These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder. Mann WA; Stassen F; Huffman W; Kinter LB J Pharmacol Exp Ther; 1986 Aug; 238(2):401-6. PubMed ID: 3090234 [TBL] [Abstract][Full Text] [Related]
8. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists. Manning M; Stoev S; Cheng LL; Wo NC; Chan WY J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312 [TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationships of novel alpha-melanocyte-stimulating hormone inhibitors. Sawyer TK; Staples DJ; Castrucci AM; Hadley ME Pept Res; 1989; 2(1):140-6. PubMed ID: 2562482 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of leiurotoxin I analogs lacking one disulfide bridge: evidence that disulfide pairing 3-21 is not required for full toxin activity. Sabatier JM; Lecomte C; Mabrouk K; Darbon H; Oughideni R; Canarelli S; Rochat H; Martin-Eauclaire MF; van Rietschoten J Biochemistry; 1996 Aug; 35(33):10641-7. PubMed ID: 8718853 [TBL] [Abstract][Full Text] [Related]
15. A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity. Huffman WF; Albrightson-Winslow C; Brickson B; Bryan HG; Caldwell N; Dytko G; Eggleston DS; Kinter LB; Moore ML; Newlander KA J Med Chem; 1989 Apr; 32(4):880-4. PubMed ID: 2522994 [TBL] [Abstract][Full Text] [Related]
16. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes. Torres BA; Johnson HM J Immunol; 1988 Apr; 140(7):2179-83. PubMed ID: 2965181 [TBL] [Abstract][Full Text] [Related]
17. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8. Flouret G; Chaloin O; Slaninová J J Pept Sci; 2003 Jun; 9(6):393-401. PubMed ID: 12846485 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. Stassen FL; Erickson RW; Huffman WF; Stefankiewicz J; Sulat L; Wiebelhaus VD J Pharmacol Exp Ther; 1982 Oct; 223(1):50-4. PubMed ID: 7120127 [TBL] [Abstract][Full Text] [Related]
19. A proton magnetic resonance study of two synthetic agonist-antagonist pairs of bradykinin analogues. Otter A; Bigler P; Stewart JM; Kotovych G Biopolymers; 1993 May; 33(5):769-80. PubMed ID: 8393713 [TBL] [Abstract][Full Text] [Related]
20. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity. Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]